“Johnson & Johnson” vaccine against the Coronavirus stimulates a strong immune response in early trials

0
9


Dubai, United Arab Emirates (CNN) – Early trials showed that a single dose of Johnson & Johnson’s experimental vaccine against the Coronavirus stimulated an immune response in nearly all volunteers, with minimal side effects.

The company expects to report details of the more advanced trials later this month, and hopes to apply for a license to use from the FDA soon after.

And the researchers who tested the vaccine in a combined trial of the first and second stages, which aims to demonstrate the safety of the vaccine, found that one or two doses of the vaccine stimulated a response to the antibodies and T cells against the Corona virus.

The trials were not designed to show whether the vaccine protects people from infection with the Coronavirus or its symptoms, as this is what the ongoing third phase trials are designed for.

An international team of researchers in the New England Journal of Medicine, who conducted trials of the vaccine on nearly 800 volunteers, wrote that early trials showed that it was safe and potentially effective.

In the Netherlands, the United States and Belgium, researchers conducted vaccine trials on a group of people aged 65 years or older and on a group between the ages of 18 and 55.

The vaccination neutralized the antibodies, which is expected to stop the virus from infecting cells, in 90% of all participants by the twenty-ninth day after receiving the first dose of the vaccine, and in each of them by two months after receiving the first dose.

The researchers reported that levels of these antibodies remained stable for at least 71 days.

The US Food and Drug Administration granted a license to use two of the Coronavirus vaccines, one developed by Pfizer with its partner, Bio-Tech, and the other from Moderna, both of which showed 95% effectiveness in preventing symptomatic disease during phase trials. Third, they both use a new vaccine technology, messenger RNA.

Janssen Pharmaceuticals, the vaccine arm of Johnson & Johnson, is using a different method for its vaccine, called AD26.Cov2S, as it uses a weak version of the common cold virus called adenovirus 26 to transfer the genetic material from The virus enters the body, which causes human cells to produce parts of the virus, which the immune system then recognizes.

The researchers wrote that a single dose of the AD26. Kov2S vaccine stimulated a strong humoral response in the majority of vaccine recipients, with neutralizing antibodies appearing in more than 90% of the participants, regardless of age group or vaccine dose.

The researchers added, “The effective single-dose Covid-19 vaccine has clear logistical advantages compared to the two-dose vaccine, especially during the pandemic.”

The company is studying whether a second dose of the vaccine increases the effectiveness or durability of the immune response.

Side effects included symptoms such as headache, body aches and, in rare cases, fever.

“The company expects to announce data for the third stage of the Janssen vaccine candidate against Covid-19 from a single dose in late January 2021,” Johnson & Johnson said in a statement, adding that “since this experiment depends on disease events, the timing is approximate.”

The company indicated that “if the single-dose vaccine proves to be safe and effective, the company expects to submit an application for an emergency use license from the US Food and Drug Administration shortly thereafter, with other regulatory applications being introduced around the world later.”

All companies that develop vaccines against the Corona virus manufacture doses even during their trials, so that they can directly introduce them in the event that they obtain a license to use by the US Food and Drug Administration.

And Johnson & Johnson has been contracted to provide 100 million doses of its vaccine to the United States government, if it obtains an emergency use license by the US Food and Drug Administration.

The New York Times reported on Wednesday that Johnson & Johnson was behind schedule in its production.

Johnson & Johnson said in a statement on Wednesday, “We are eager for more tools to help stop the pandemic. At the same time, it is too early to go into the details of our candidate vaccine supplies, given that we do not have the data for the third stage, and we have not submitted an application or We were granted an emergency use permit. “





LEAVE A REPLY

Please enter your comment!
Please enter your name here